RNY3: RNY3 is a small RNA that is overexpressed in various cancer cells and is associated with advanced stage and grade in bladder cancer [PMC5681827]. It is one of the four members of the human YRNA family, along with RNY1, RNY4, and RNY5 [PMC7056873]. RNY3, along with other mRNA transcripts such as MAGT1, MAK3K1, PHLDB2, SCARB1, SNAPC2, and FSP1, is significantly upregulated in cancer-associated fibroblasts (CAFs), indicating aberrant signaling pathways involved in cell survival, proliferation, and migration [PMC9856041]. In malnourished individuals, RNY3 expression is inhibited along with other immunomodulatory genes such as PRL (Prolactin), IFNL1 (type III interferon), AREG (Amphiregulin), IFNA2 (type I interferon), and IFN-γ (type II interferon) [PMC9554585]. Mouse/human siRNA against the terminal loop of RNY3 has been used to study its effects on IL13 mRNA levels [PMC5386355]. In addition to its role in cancer cells and fibroblasts, RNY3 has been identified as one of the YRNA sequences representing an average of 26.1% of reads in a study on YRNA-associated sequences [PMC6356785]. Furthermore, histone mRNAs and RNA polymerase III transcribed small noncoding RNAs such as Vaultrc5 have been found to be upregulated along with Rny1,Rpph1,Rny4,andRny3[PMC6075040].